Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2021 Results - Earnings Call Transcript
01:52pm, Sunday, 09'th May 2021
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2021 Results - Earnings Call Transcript
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
06:25pm, Wednesday, 05'th May 2021
AxoGen (AXGN) delivered earnings and revenue surprises of 52.94% and 8.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Axogen Q1 Earnings
04:49pm, Wednesday, 05'th May 2021
Shares of Axogen (NASDAQ:AXGN) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 57.89% over the past year to ($0.08), which be
Recovering Trauma Cases Should Highlight AxoGen's Improving Execution
12:19pm, Thursday, 11'th Mar 2021
AxoGen has reported two consecutive quarters of double-digit growth despite lower trauma presentations during the pandemic and restrictions on marketing/training efforts. Clinical data continue to sup
Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
04:01pm, Monday, 01'st Mar 2021
ALACHUA, Fla., March 01, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2020 Results - Earnings Call Transcript
11:27pm, Monday, 22'nd Feb 2021
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2020 Results - Earnings Call Transcript
Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results
04:01pm, Monday, 22'nd Feb 2021
ALACHUA, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fi
Axogen, Inc. to Participate at Upcoming February Investor Conferences
07:00am, Thursday, 04'th Feb 2021
ALACHUA, Fla., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves
A Trio of Fast Growing Revenue Stock Picks
09:45am, Monday, 11'th Jan 2021
The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of nearly 2% per annum over the past five years. The share price of the be
Axogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings
07:00am, Tuesday, 05'th Jan 2021
Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platform for ne
Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration
07:00am, Wednesday, 23'rd Dec 2020
ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves,
AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement
08:08pm, Sunday, 20'th Dec 2020
AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement
Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum
07:00am, Wednesday, 04'th Nov 2020
ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves,
Axogen, Inc. Reports Third Quarter 2020 Financial Results
04:01pm, Thursday, 29'th Oct 2020
ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported fi
AxoGen (NASDAQ:AXGN) Stock Rating Upgraded by BidaskClub
04:12am, Sunday, 18'th Oct 2020
AxoGen (NASDAQ:AXGN) was upgraded by equities research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Friday, BidAskClub reports. Several other research a
